British drugmaker GlaxoSmithKline Plc is collaborating with the Coalition for Ep...
FILE PHOTO: A GlaxoSmithKline logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls/File Photo
GSK will make its “adjuvant platform technology” available for developing a vaccine against the 2019-nCoV virus, according to the statement. GSK will engage with entities funded by the CEPI with the first of these agreements having been signed between the British drugmaker and Australia’s University of Queensland, the statement added.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Inside the Company That's Hot Wiring Vaccine Research in the Race to Combat the CoronavirusResearchers at the National Institutes of Health are working with biotech company Moderna Therapeutics to develop and test a vaccine against the latest viral outbreak
Baca lebih lajut »
Opinion | Pharma to the RescueFrom WSJopinion: Advances in drug research mean a vaccine for the coronavirus could be in human trials by April, writes The Editorial Board
Baca lebih lajut »
How far away is a coronavirus vaccine?Over 200 people have died since 2019-nCoV emerged in China late last year.
Baca lebih lajut »
Investors rush into biotechs working on coronavirus vaccineSome biotech firms have been outperforming the market over the past few weeks on their treatment initiatives.
Baca lebih lajut »
China's Hubei reports 45 new coronavirus deaths, total at 249China's Hubei province, the epicentre of a coronavirus epidemic, reported 4...
Baca lebih lajut »
China's total coronavirus deaths hit 259 by end of Jan. 31, up 46: state mediaThe total number of deaths from a coronavirus epidemic in China had reached 259 ...
Baca lebih lajut »